The Immunomodulatory Imbalance in Patients with Ketamine Cystitis

Gang-Yi Fan,1 Juin-Hong Cherng,2 Shu-Jen Chang,3 Raju Poongodi,2 Adrienne Chang,4 Sheng-Tang Wu,5 and En Meng5

1Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan
2Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan
3Faculty of Dentistry, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
4Department of Chemistry, New York University Abu Dhabi, Abu Dhabi, UAE
5Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

Correspondence should be addressed to En Meng; en.meng@gmail.com

Received 30 July 2017; Accepted 26 September 2017; Published 24 October 2017

Academic Editor: Robert Stoehr

Copyright © 2017 Gang-Yi Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The pathogenesis of ketamine cystitis (KC) has been recently linked with immune response to patients but the same has not yet been established. Hence, this study aims to propose a possible immune mechanism of irreversible bladder damage caused by KC. A total of 53 KC patients and 21 healthy volunteers as controls have been retrospectively assessed. The levels of serum immunoglobulin E (IgE), IL-6, and IFN-γ of KC patients were significantly higher than those of controls, whereas the TGF-β levels of KC patients substantially reduced but the IL-2 and IL-4 levels of KC patients were comparable to those of controls. Moreover, the KC patients had significantly higher counts of TH1, TH2, and TH17 cells than those of controls. The immune response of KC users may begin with the IL-6 production and differentiation of TH17 and may be followed by alternating between high expression of TH1 and TH2. The IL-6 may further suppress the TREG cells which can aggravate chronic inflammation in KC patients and the imbalance in TH17 and TREG cells may involve the pathogenesis of KC. Further investigation is needed to define the role of IL-6 in TH1/TH2/TH17-regulated signaling pathway in ketamine-induced cystitis.

1. Introduction

Ketamine is a phencyclidine hydrochloride derivative which is mainly used for starting and maintaining anesthesia [1]. It induces a dissociative, trance-like state in which the patient is unable to respond to external stimuli [2]. Chronic abuse has been associated with an out-of-body experience known as the K-hole phenomenon [3]. Due to low price and availability, ketamine has been increasingly used as a recreational drug which affects the central nervous and cardiovascular systems [4]. The chronic ketamine abuse may cause ulcerative cystitis and dysfunction of the lower urinary tract, both of which have been recognized as a new disease entity, called “ketamine cystitis” (KC). The number of KC patients has been increased dramatically in the past decade [5]. The KC shares many common histopathological features with interstitial cystitis/bladder pain syndrome (IC/BPS), including urothelial ulceration, inflammatory cell infiltration, and varying degrees of bladder wall fibrosis [6]. Among them, the long-term bladder inflammation may cause fibrosis of the bladder wall and, eventually, a contracted bladder [7]. In particular, the eosinophil and mast cell infiltration are frequently seen in human bladder tissue after long-term ketamine use [6, 8, 9]. A recent study reported that the KC patients had higher serum immunoglobulin E (IgE) than patients with IC/BPS or acute bacterial cystitis, which may be associated with bladder pain severity and small maximal bladder capacity in KC patients [10]. Therefore, the immune response to ketamine may play a key role in the pathogenesis of KC. However, only little knowledge on the immune activity in KC patients has been established.

On the other hand, the pivotal immune events of immune diseases are the development of antigen-specific effector T helper type 2 (TH2) cells, TH1 cells, or the recently defined...
2. Materials and Methods

2.1. Patient and Sample Collection. A total of 53 KC patients and 21 healthy volunteers were included in this retrospective study. Each of the KC patients showed symptoms of lower urinary tract irritation, such as urgency, nocturia, and frequency. The urine and blood samples of each patient were collected for analysis. The urine test panel was conducted for pH and urinary tract irritation, such asurgency,nocturia,andfrequency. Among the 53 KC patients, 26 patients underwent full clinical examination and cystoscopy with hydrodistention, and 3 patients refused bladder biopsy. Table 2 lists the clinical usage was enrolled in this study. The chronic ketamine users are 31 males and 22 females in which their age was 23.84 ± 4.74 years (mean ± SD). The average duration of ketamine usage was 50.44 ± 4.99 months for KC patients (Table 1).

2.2. Histological Analysis. The paraffinized sections (0.6 μm) of each patient (3–10 sections/patient) were stained with Gill’s hematoxylin V (MUTO, Tokyo, Japan) and 1% eosin alcohol solution (MUTO; H&E). The obtained H&E slides were examined under a light microscope (Olympus BX51; Olympus, Tokyo, Japan).

2.3. Serum Cytokine Assay. The serum samples were collected and the production of cytokine/chemokines was quantified by the MILLIPLEX™ MAP Human Cytokine/Chemokine Kit (Millipore Corp., Billerica, MA). Serum specimens were drawn from 21 KC patients (13 males, 8 females) and 21 volunteers (17 males, 4 females). Eight-parameter logistic standard curves were set and data were processed with MILLIPLEX® Analyst 5.1 software. The cytokines levels IL-1, IL-2, IL-4, IL-5, IL-6, IL-17, TNF-α, IFN-γ, TGF-β1, TGF-β2, and TGF-β3 were analyzed by enzyme-linked immunosorbent assay (ELISA).

2.4. T<sub>H</sub>1/T<sub>H</sub>2/T<sub>H</sub>17 Determination in Peripheral Blood Mononuclear Cells (PBMCs). Peripheral blood was collected from 13 KC patients (10 males, 3 females) and 13 volunteers (10 males, 3 females) by venous puncture and collected into preservative-free heparin. The PBMCs were isolated by means of Ficoll-Plaque Plus density gradient centrifugation (Amersham Biosciences, NJ, USA). For intracellular staining, PBMCs at a concentration of 1–10 million cells/mL were stained for 5 h with phorbol 12-myristate 13-acetate (PMA)/ionomycin at 50 ng/mL and 1 μg/mL, respectively. 4 μL of BD GolgiStop™ was added for every 6 mL of cell culture and mixed thoroughly. The PBMCs were then fixed in BD Cytofix™ Fixation Buffer and made permeable with BD Phosflow™ Perm/Wash Buffer. The percentages of T<sub>H</sub>1 and T<sub>H</sub>17 in CD4<sup>+</sup> T cells were obtained through flow-cytometric analysis using the BD Human T<sub>H</sub>1/T<sub>H</sub>2/T<sub>H</sub>17 Phenotyping Kit, which has a four-color cocktail of fluorochrome antibodies specific for Human CD4 (PERCP-CY5.5 Clone: SK3), IFN-γ (for T<sub>H</sub>1, FITC Clone: B27), IL-4 (for T<sub>H</sub>2, APC Clone: MP4-25D2), and IL-17A (for T<sub>H</sub>17, PE Clone: N49-653).

2.5. Statistical Analysis. All the data were evaluated by analysis of variance (Sigma plot, 2001). The values are reported as mean ± SD of at least three experiments. Paired t-test and chi-square test were employed for comparison between two groups, and p values ≤ 0.05 were considered statistically significant. The correlation coefficient (r) was applied between the serum cytokine levels.

3. Results

A total of 74 subjects (53 KC users and 21 nonusers) were enrolled in this study. The chronic ketamine users are 31 males and 22 females in which their age was 23.84 ± 4.74 years (mean ± SD). The average duration of ketamine usage was 50.44 ± 4.99 months for KC patients (Table 1). Among the 53 KC patients, 26 patients underwent full clinical examination and cystoscopy with hydrodistention, and 3 patients refused bladder biopsy. Table 2 lists the clinical information and serum Ig levels. The laboratory studies revealed an elevated creatinine (1.25 ± 0.42 mg/dL) and IgE levels (261.59 ± 56.03 IU/mL) with positive CBCs and WBCs in urine analysis. Further, the urothelial biopsies were performed a week after urine and blood sample collection. And, the tissue histology analyzed using hematoxylin and eosin (H&E) stains. The urinary bladder mucosa revealed denuded bladder epithelium, hemorrhage (Figures 1(a) and 1(c)), acute and chronic inflammation as well as the presence of
Table 1: Demographic and laboratory characteristics of KC patients. *SD: standard deviation. The normal range of each characteristic is obtained from Department of Clinical Pathology, Tri-Service General Hospital, Taipei, Taiwan.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n, n (%) or mean (SD)*</th>
<th>Unit</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male : female ratio</td>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Age, years</td>
<td>23.84 (4.74)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Duration of ketamine abuse, months</td>
<td>50.44 (4.99)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>WBC</td>
<td>9.32 (0.45)</td>
<td>10 × 3/uL</td>
<td>4.50–11.00</td>
</tr>
<tr>
<td>Neutrophil</td>
<td>63.28 (1.5)</td>
<td>%</td>
<td>40.0–74.0</td>
</tr>
<tr>
<td>Lymphocyte</td>
<td>25.71 (1.15)</td>
<td>%</td>
<td>19.0–48.0</td>
</tr>
<tr>
<td>Monocyte</td>
<td>6.34 (0.37)</td>
<td>%</td>
<td>3.4–9.0</td>
</tr>
<tr>
<td>Eosinophil</td>
<td>4.11 (0.77)</td>
<td>%</td>
<td>0.0–7.0</td>
</tr>
<tr>
<td>pH</td>
<td>6.31 (0.1)</td>
<td>—</td>
<td>5.0–8.0</td>
</tr>
<tr>
<td>Urine RBC</td>
<td>6.87 (2.168)</td>
<td>HPF</td>
<td>0–5</td>
</tr>
<tr>
<td>Urine WBC</td>
<td>16.11 (4)</td>
<td>HPF</td>
<td>0–5</td>
</tr>
<tr>
<td>Epithelial cells</td>
<td>5.4 (1.91)</td>
<td>HPF</td>
<td>0–6</td>
</tr>
<tr>
<td>Creatinine</td>
<td>1.25 (0.42)</td>
<td>mg/dL</td>
<td>0.5–0.9</td>
</tr>
</tbody>
</table>

Table 2: Serum complement and immunoglobulin tests of KC patients. The normal range of each characteristic is obtained from Department of Clinical Pathology, Tri-Service General Hospital, Taipei, Taiwan.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n, n (%) or mean (SD)*</th>
<th>Unit</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>C3</td>
<td>96.48 (4.59)</td>
<td>mg/dL</td>
<td>79.0–152.0</td>
</tr>
<tr>
<td>C4</td>
<td>20.37 (1.01)</td>
<td>mg/dL</td>
<td>16.0–38.0</td>
</tr>
<tr>
<td>Immunoglobulin G</td>
<td>927.57 (51.48)</td>
<td>mg/dL</td>
<td>751–1560</td>
</tr>
<tr>
<td>Immunoglobulin M</td>
<td>108.86 (14.6)</td>
<td>mg/dL</td>
<td>46–304</td>
</tr>
<tr>
<td>Immunoglobulin E</td>
<td>261.59 (56.03)</td>
<td>IU/mL</td>
<td>&lt;165.0</td>
</tr>
</tbody>
</table>

* p < 0.05.

eosinophil, eosinophil infiltrates, and fibrosis deposition over submucosa; the stroma revealed intravascular neutrophil and eosinophil accumulation (magnified view from black box, Figures I(b) and I(d)).

Flow-cytometric analysis of KC patients showed considerably higher T_{H1} (IFN-γ, 10.94 ± 1.81 %), T_{H2} (IL-4, 10.72 ± 2.79 %), and IL-5, 11.09 ± 4.17 %), and T_{H17} (IL-17A, 7.11 ± 2.12 %; p = 0.0001) cells and also gave some representative fluorescence-activated cell sorting (FACS) plots (Figure 2). The univariate comparison of 6 cytokines in the normal and KC groups revealed a two- to ninefold increase in serum IL-6 (2-tailed p = 0.05), IL-1β, IL-5, and IL-17 expression. The serum levels of the remaining proteins, namely, IL-2 and IL-4, were not significantly increased in the KC group relative to control groups (Figure 3(a)). The distribution of all serum cytokine tests passed the Mann–Whitney U test for normality. In addition, the serum cytokine assays were used to determine the effects of ketamine on inflammatory cytokine levels which showed a remarkably increased level of TNF-α (KC versus control; 193.59 ± 282.17 versus 98.43 ± 85.48 pg/mL) and IFN-γ (369.78 ± 564.56 versus 0 pg/mL; p < 0.001) in KC cases (Figure 3(b)).

Patients with KC had significant decrease in TGF-β1 (KC versus control; = 25429.14 ± 25940.15 versus 38857.60 ± 13482.19 pg/mL; p = 0.008) and TGF-β2 (950.01 ± 498.500 versus 1236.30 ± 218.88 pg/mL; p = 0.046; Mann–Whitney U test) levels (Figure 3(c)). The TGF-β2 level was also found to lower in KC patients comparing to the controls (1068.22 ± 695.28 versus 1380.99 ± 387.45 pg/mL; p = 0.093) although there was no significance. Since the KC group revealed that the levels of TGF-β1, TGF-β2, TGF-β3 were below the level of detection in the control group, these results lend support to our hypothesis that an increase in cytokines is linked to inflammatory cells and regulation between T_{H1}, T_{H2}, and T_{H17}.

The basis of several statistical tests that result in a correlation coefficient is defined as a numerical representation of the strength and direction of a relationship. On moving to the correlation of cytokines of KC patients (Figure 4), the IL-6 was positively correlated with IL-4 (r = 0.414, p < 0.05), and IL-1β and IL-17 were positively correlated with IL-5 (r = 0.939, p < 0.001 and r = 0.840, p < 0.001). Further, the TNF-α and IFN-γ were positively correlated with IL-1β (r = 0.831, p < 0.001 and r = 0.804, p < 0.001), and TNF-α and IFN-γ were positively correlated with IL-17 (r = 0.692, p < 0.001 and r = 0.769, p < 0.001). Moreover, a direct correlation was found in TNF-α with IFN-γ (r = 0.692, p < 0.001) and IL-6 with IL-2 (r = 0.447, p < 0.01). But, IL-6 with IL-4 and IL-6 with IL-2 have found very least correlation in this study.

4. Discussion

In the current study, we have illustrated the different profiles of inflammatory cytokines and T_{H} cell expression in KC patients versus healthy controls. The differing cytokine characteristics between normal control and chronic ketamine users may allude to a possible mechanism of KC (Figure 5). In this regard, we hypothesize that the acute inflammation seen in the bladder mucosal and submucosal layer may be caused by the acute immune response of ketamine through the T_{H1} cell pathway. Ketamine may enhance the production of IL-6 which can further result in the apoptosis and shedding of epithelial and interstitial cells. In KC patients, T_{H1} and T_{H2} cells may be produced in a positive feedback loop from naïve T cells and then inhibit each other; the immune response oscillates between T_{H1} and T_{H2} cells, triggering varying symptoms and eosinophil infiltration among chronic ketamine users.

Further, we found significantly increased levels of IL-6, TNF-α, and IFN-γ with comparably higher levels of IL-1β, IL-5, and IL-17 in the serum of KC patients than those of the healthy controls. Since the cytokine, IL-6, promotes the development of T_{H17} cells, the higher level of IL-6 in KC patients suggests that the balance between T_{H17} and T_{H1} responses as well as IL-6 production is dysregulated in KC, which resulted in the reinforced feedback that increases the IL-1β and IL-17.
production in CD4+ T cells. This increase may contribute to disease pathogenesis (Figure 5). Therefore, the function of IL-6 might assist in the knowledge of its complex role in inflammation: throughout acute inflammation, the IL-6 might favor the resolution from neutrophilic infiltrate as well as favor the initiation from the immune response in chronic inflammation. Further, the IL-6 induces the development of Th17 cells from naive T cells and, together with TGF-β, may boost the mononuclear-cell infiltrate and take part in disease pathogenesis [14].

T_{REG} cells have been recognized as a suppressor of effector T cells and, thus, are thought to control the Th1, Th2, and Th17 responses. Our results showed low concentration of T_{REG} related serum cytokines, IL-2 and TGF-β, which may explain the persistent inflammation in the KC patients (Figures 3(a) and 3(c)). It is to be noted that the TGF-β3 regulates molecules involved in cellular adhesion and extracellular matrix (ECM) formation in tissue [15]. So, the lower concentration of TGF-β3 in the KC group suggests the impaired healing capability of bladder epithelial lining in chronic KC patients. The elevated IL-17 level and reduced TGF-β level showed that the CD4+ T cell differentiation is biased away from T_{REG} cells toward the Th17 cell phenotype [16]. The differentiation of CD4+ cells generates the Th1 and Th2 phenotypes with the same receptor specificity, indicating the competition for antigenic stimulation, mediated by antigen-presenting cells (APCs), combined with cytokine-mediated cross-suppression between phenotypes to yield a response that is eventually dominated by T helper cells that are uniform in both receptor specificity and cytokine secretion phenotype. We found a different T helper cell phenotype distribution that the Th1, Th2, and Th17 receptors were all expressed in PBMCs (Figure 2), consistent with recent data [17]. We subsequently analyzed the serum cytokine secreted from the T helper cells in KC patients.

Previous studies have shown that many, but not all, of the effects of IFN-γ paracrine can be stimulated to Th1 cells to secrete lymphokines [18]. The increase in IFN-γ...
Figure 2: Elevated CD4^+ T_H1 (IFN-γ), T_H2 (IL-4 and IL-5), and T_H17 (IL-17a) populations in human PBMC of KC patients versus healthy volunteers. Peripheral T cells were stimulated with 1 ng/ml PMA, 1 μM ionomycin, and 3 μM monensin. Intracellular staining (FACS) was done after 6 hours. Some representative FACS plots are given in (b).
paracrine may stimulate the \( T_{H1} \) cells to secrete their own lymphokines TNF-\( \alpha \), IFN-\( \gamma \), and IL-6 (Figure 3(b)). The IL-6, combined with TGF-\( \beta \) and IL-1\( \beta \), induces the differentiation of \( T_{H17} \) from naive cells and then enhances the IL-17 secretion (Figure 3(a)). IL-6 is an important switch that determines whether \( T_{H17} \) or \( T_{REG} \) cells are generated when TGF-\( \beta \) is present; TGF-\( \beta 1 \) has been known to inhibit the differentiation of \( T_{H11} \) and \( T_{H2} \) cells [19, 20]. Hence, increases in IL-6 and IL-1\( \beta \) noted in KC patients may cause an offsetting response to the increase in TGF-\( \beta 1 \), TGF-\( \beta 2 \), and TGF-\( \beta 3 \) (Figures 3(a) and 3(c)). IL-6 and IL-1\( \beta \) have been found to be increased in inflammatory urinary tract disease, indicating that IL-6 may also play an essential role in bladder dysfunction related to urinary tract infection [21].

IL-6 is a multifunctional cytokine which is produced at sites of tissue inflammation. It has been demonstrated that IL-6 derived from APCs is able to initiate IL-4 production in naive CD4\( ^+ \) T cells, thereby polarizing these cells into \( T_{H2} \) cells [22]. IL-4 targets B cells and mast cells, resulting in the production of IgE and inhibits IL-6 production; IL-5 targets eosinophils. The increased IFN-\( \gamma \) may induce differentiation of CD4\( ^+ \) cells into \( T_{H1} \) cells and suppress the proliferation of \( T_{H2} \) cells, causing apoptosis of eosinophils and inhibiting IgE production [23]. These results demonstrated that IL-6 signaling has the ability to enhance the production of TGF-\( \beta 2 \) related cytokines (i.e., IL-4 and IL-5) via CD4+ T cell pathway. As regards KC disease, a strong correlation between the frequencies of IL-17, TNF-\( \alpha \), and IFN-\( \gamma \) in KC patients has been observed (Figure 4). Previous studies have indicated that TGF-\( \alpha \) and IL-17 have synergistic effects with many other factors, including IL-1\( \beta \), IL-22, and IFN-\( \gamma \) [24]. The infiltrations of \( T_{H1} \) and \( T_{H17} \) cells have been associated with the pathogenesis of autoimmune disorders.
**Figure 4:** Correlation between various circulating cytokines in patients with ketamine cystitis.

\( \text{T}_{H17} \) effector cells are induced in parallel to \( \text{T}_{H1} \), and, like \( \text{T}_{H1} \), polarized \( \text{T}_{H17} \) cells have the capacity to induce inflammation and autoimmune disease [16]. The main function of IL-17-secreting T cells is to mediate inflammation, by stimulating production of inflammatory cytokines that promote the recruitment of neutrophils and macrophages [25]. Although we observed elevated IL-1\( \beta \) levels, the reduction of TGF-\( \beta \) is consistent with the elevation of IL-6 and IL-17 and may reflect \( \text{T}_{H17} \) cell activity rather than \( \text{T}_{REG} \) cell activity. In addition, the elevated levels of \( \text{T}_{H2} \) cells and their associated effector cytokines, IL-5, were correlated with IL-1\( \beta \) and IL-17, indicating a central role for \( \text{T}_{H17} \)-mediated immune responses associated with IL-6; IL-6 promotes \( \text{T}_{H17} \) but suppresses \( \text{T}_{REG} \) differentiation in KC disease [26]. Since the IL-5 and IL-17A regulate the production of specific-IgE in vivo [27], these results may explain the reason of increased IgE level and also can convince the eosinophil infiltration in the bladder suburothelium that was found in KC patients.

Study limitations include small sample size and the single time point serum measurement. The increased cytokine levels in KC patients reflect that the ongoing bladder inflammation noted at the bladder ulcer site is to be confirmed by further
Ketamine may cause acute inflammation through Th1 pathway. Ketamine may also promote IL-6 generation which links to the generation or maintenance of Th17 cell effector functions and then causes tissue destruction and collagen deposition. IL-6 promotes the differentiation of Th17 cells by enhancing endogenous IL-4 production and increases the production of IgE. IL-6 may also suppress TREG cells and therefore sustain the activation of Th1 and Th2 cells. Reinforced feedback of IL-6 increases the production of IL-1β and IL-17 from CD4+ T cells.

Investigation. Further investigation is necessary to clarify the role of IL-6 in Th1/Th2/Th17-regulated signaling pathway in ketamine-induced cystitis. These preliminary results pieced together from data collected from ketamine patients offer a possible mechanism of ketamine-associated cystitis. However, further in vivo tests would confirm the effects of various cytokine concentrations on T cell differentiation, particularly the initial concentrations of TGF-β and IL-6. In vivo experiments would also allow us to control the daily amount of ketamine and the bladder could be analyzed at various stages of the inflammatory response to confirm our theory.

5. Conclusion

Ketamine may cause acute inflammation through Th1 pathway and elicit secondary mediator IL-6 generation which links to the dynamic balance of Th17/TREG cell effector functions. The IL-6 may cause tissue destruction and collagen deposition via Th17 cells activation and suppress TREG cells resulting in sustained activation of Th1 and Th2 cells. Further, the IL-6 may promote the differentiation of Th17 cells by enhancing endogenous IL-4 production and increase the production of IgE in KC patients. This is associated with Th17-mediated chronic inflammatory response. In addition, the low concentration of TGF-β3 in KC patients implied a suppression of TREG function, which may cause the tissue damage and immune-mediated inflammation. This will subsequently impair the healing of urothelium in KC patients.

Ethical Approval

This study was approved by the Institutional Review Board, Ministry of Science and Technology, National Defense Medical Center, Veterans General Hospital, and Tri-Service General Hospital, Taipei, Taiwan. There was no patient identifying information included in this manuscript. All the study subjects were strictly adhered to the Declaration of Helsinki 2012.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

En Meng and Juin-Hong Cherng were involved in the conception and design of the experiments. Gang-Yi Fan, Juin-Hong Cherng, Shu-Jen Chang, Raju Poongodi, Adrienne Chang, Sheng-Tang Wu, and En Meng were involved in the
collection, analysis, and interpretation of data. Juin-Hong Cherng, Raju Poongodi, and En Meng drafted the article.

Acknowledgments

This study was supported by the Ministry of Science and Technology (Grant nos. 103-2314-B-016-035-MY2 and 105-2314-B-016-010); National Defense Medical Center (Grant nos. MAB-105-095 and MAB-106-051); Tri-Service General Hospital, Taipei Veterans General Hospital Joint Research Program (Grant no. DVI104-13); Tri-Service General Hospital, Taiwan (Grant nos. TSGH-C104-056, TSGH-105-050, and TSGH-C106-042).

References


